Tag: <span>Schizophrenia</span>

Home / Schizophrenia
Post

People with schizophrenia have altered ability to visually perceive contrast, researchers find

by University of Barcelona (A) Illustration of Three Trials to Measure Contrast Sensitivity. (B) Contrast Sensitivity in Individuals with Schizophrenia and Healthy Controls for Schwartz and Winstead (1985). A Small Jitter in Spatial Frequency Between Groups is Added to Minimize Overlap. Error Bars are Standard Errors of the Mean. (C) Estimated Hedges’ g for the Same...

Post

Brain-cell ‘periodic table’ for psychiatric disorders reveals new schizophrenia clues

by Bruce Goldman, Stanford University Approach for systematically testing 461 human brain cell types for association with schizophrenia (and other phenotypes tested). Credit: Nature Neuroscience (2025). DOI: 10.1038/s41593-024-01834-w Stanford Medicine scientists are generating a periodic table of sorts for psychiatric disorders, providing a better understanding of these conditions and paving the way toward targeted treatment. By combining two...

Post

Study reveals immune system changes linked to schizophrenia and treatment resistance

by Agency for Science, Technology and Research (A*STAR), Singapore Credit: Unsplash/CC0 Public Domain Researchers from Singapore’s National Healthcare Group (NHG)’s Institute of Mental Health (IMH) and Agency for Science, Technology and Research (A*STAR) have made strides in understanding the connection between the immune system and resistance to antipsychotic medications in schizophrenia, using changes in immune cell...

Post

COULD AN EYE TEST SPOT SCHIZOPHRENIA?

JANUARY 2ND, 2025POSTED BY YALE (Credit: Getty Images) SHARE THIS ARTICLE You are free to share this article under the Attribution 4.0 International license. TAGS UNIVERSITY  YALE UNIVERSITY Could complex beliefs like paranoia have roots in something as basic as vision? A new study finds evidence that they might. When completing a visual perception task, in which participants...

Post

Schizophrenia: Researchers observe disease processes in nerve cells

by Jörg Schäfer, NMI Naturwissenschaftliches und Medizinisches Institut in Reutlingen Example ICC images of marker expression in iPSC (left) and NPC (right) obtained by high-content microscopy. Credit: BMC Psychiatry (2024). DOI: 10.1186/s12888-024-06127-x Up to now, schizophrenia has mainly been treated symptomatically, as little is known about the exact underlying processes. Researchers at the NMI Natural and Medical...

Post

Genetic risk for schizophrenia linked to a malformed skull

by St. Jude Children’s Research Hospital Research from the Zakharenko lab, St. Jude Department of Developmental Neurobiology published in Nature Communications revealed a gene deleted in 22q11.2 deletion syndrome results in malformed regions of the cerebellum, but the defect is a result of a local skull deformity. Pictured: first author on the paper Tae-Yeon Eom, PhD....

Post

Intermittent theta burst stimulation found to more effective for treating schizophrenia symptoms than other approaches

by Fujita Health University In a study published in JAMA Network Open, researchers from Fujita Health University, Japan conducted a systematic review and network meta-analysis using published data and verify the efficacy and safety of TBS protocols for schizophrenia. Credit: Public Relations Department, Fujita Health University, Japan Schizophrenia, which is characterized by positive symptoms (e.g., hallucinations and...

Post

Brain plasticity expert Peter Falkai discusses new pathways for treating schizophrenia

Max Planck Institute director Prof. Peter Falkai shares groundbreaking research insights in exclusive Genomic Press InterviewReports and Proceedings Genomic Press image:  Peter Falkai, MD, PhD, Munich University Hospital, Germanyview more  Credit: Peter Falkai, MD, PhD MUNICH, Germany, 19 November 2024 – In a comprehensive Genomic Press Interview, distinguished psychiatrist Professor Peter Falkai suggests promising new directions...

Post

FDA approves Cobenfy for adults with schizophrenia

by Lori Solomon The U.S. Food and Drug Administration has approved Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic agonist, for the treatment of schizophrenia in adults. The oral medication represents the first new class of medicine in several decades and selectively targets M1 and M4 receptors in the brain, without blocking D2 receptors. The approval is...

Post

Psychedelic use linked to increased risk of schizophrenia, study finds

Peer-Reviewed Publication Institute for Clinical Evaluative Sciences image:  Infographic: Myran et al. JAMA Psych. 2024view more  Credit: ICES Ottawa, ON, November 13, 2024 – Individuals with emergency department visits involving hallucinogen use are at high risk of developing schizophrenia, according to a new study from researchers at ICES, The Ottawa Hospital, University of Ottawa’s Department of Family...